Not a good buy right now for an impatient trader: trend is decisively bearish (SMA_200 > SMA_20 > SMA_5) with worsening downside momentum (MACD histogram negative and expanding).
Although RSI(6)=16.8 is deeply oversold and price is sitting on S1 (~2.259), this is a “falling knife” setup without a confirmed reversal signal or Intellectia buy signal.
Options positioning is call-heavy (PCR 0.22) but implied volatility is extremely elevated (30D IV ~366%), which usually means expensive risk and unstable price action rather than a clean long entry.
With no supportive news flow and earnings on 2026-02-17 (after hours) as the next major catalyst, the risk/reward for buying immediately is unfavorable.
Sentiment (positioning): Put/Call OI ratio = 0.22 (calls dominate) → speculative bullish bias in open interest.
Flow (today): Put volume = 0, call volume = 31 → one-sided call activity, but total volume is small.
Volatility: 30D IV ~366% vs historical vol ~103.6% and IV percentile ~74.7 → options are pricing extreme moves; risk is expensive for buyers.
IV trend: IV 5D avg ~320.7 vs IV 10D avg ~259.8 → implied volatility has been rising recently (often tied to event risk / uncertainty).
Takeaway: Options market leans bullish, but the very high IV makes “buying stock now” less attractive unless you expect an immediate sharp rebound.
Technical Summary
Sell
9
Buy
4
Positive Catalysts
if buyers step in.
Neutral/Negative Catalysts
can increase uncertainty; current IV suggests the market expects big movement.
Financial Performance
Latest quarter provided: 2025/Q3.
Revenue: 697,000, up +1266.67% YoY (growth off a very small base).
Profitability: Net income is still deeply negative at -352,768,000 (despite YoY improvement per dataset, losses remain extremely large).
EPS: -32.89, down -95.55% YoY (per dataset) → per-share performance remains very weak.
Gross margin: Reported as 85.22, down -130.39% YoY (data suggests severe margin deterioration/instability).
Overall: Revenue growth exists, but fundamentals shown are dominated by heavy losses and unstable margins—not supportive of an “impatient buy-now” setup.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating changes or price target updates were provided in the data.
Wall Street pros/cons view (based on provided info only):
Pros: Top-line growth is sharply higher YoY in 2025/Q3.
Cons: Extremely large losses, very negative EPS, and weak/unstable margin metrics—would likely keep professional sentiment cautious without evidence of a turnaround.
Influential/political trading: No recent congress trading data available; insiders and hedge funds show neutral activity (no significant recent trend).
Wall Street analysts forecast HSDT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HSDT is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Analyst Rating
0
Wall Street analysts forecast HSDT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HSDT is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
